Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks, has announced its participation in the Inaugural Guggenheim Securities Healthcare Innovation Conference. The event will take place at the InterContinental Boston from November 11-13, 2024.
The company will participate in a fireside chat on Wednesday, November 13, at 9:30 a.m. ET. A live audio webcast will be available on the Investors section of the Pharvaris website, with the replay accessible for 30 days after the presentation.
Details
News Market Reaction – PHVS
The recorded move for PHVS in the trading session of this news was -6.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows:
| Format: | Fireside Chat | |
| Date, time: | Wednesday, November 13, 9:30 a.m. ET | |
| Webcast Link | ||
A live audio webcast will also be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replay will be available on Pharvaris’ website for 30 days following the presentation.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE by year-end 2024. For more information, visit https://pharvaris.com/.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.